Clinical Post-SARS-CoV-2 Infection Scenarios in Vaccinated and Non-Vaccinated Cancer Patients in Three German Cancer Centers: A Retrospective Analysis

Evgenii Shumilov*, Lena Aperdannier, Nicole Schmidt, Christoph Szuszies, Albrecht Neesse, Petra Hoffknecht, Cyrus Khandanpour, Jan Henrik Mikesch, Matthias Stelljes, Göran Ramin Boeckel, Phil Robin Tepasse, Lea Reitnauer, Raphael Koch, Justin Hasenkamp, Ulrike Bacher, Simone Scheithauer, Lorenz Trümper, Norbert Schmitz, Gerald Wulf, Andrea KerkhoffGeorg Lenz, Carolin Krekeler, Annalen Bleckmann*

*Corresponding author for this work
3 Citations (Scopus)

Abstract

COVID-19 vaccines have become an integral element in the protection of cancer patients against SARS-CoV-2. To date, there are no direct comparisons of the course of COVID-19 infection in cancer patients between the pre- and post-vaccine era. We analyzed SARS-CoV-2 infections and their impact on cancer in COVID-19 vaccinated and non-vaccinated patients from three German cancer centers. Overall, 133 patients with SARS-CoV-2 were enrolled in pre- and post-vaccine eras: 84 non-vaccinated and 49 vaccinated, respectively. A mild course of COVID-19 was documented more frequently in vaccinated patients (49% vs. 29%), while the frequency of severe and critical courses occurred in approximately one-half of the non-vaccinated patients (22% vs. 42%, p = 0.023). Particularly, patients with hematologic neoplasms benefited from vaccination in this context (p = 0.031). Admissions to intermediate- and intensive-care units and the necessity of non-invasive and invasive respiratory support were reduced by 71% and 50% among vaccinated patients, respectively. The median length of admission was 11 days for non-vaccinated and 5 days for vaccinated patients (p = 0.002). COVID-19 mortality was reduced by 83% in vaccinated patients (p = 0.046). Finally, the median time from SARS-CoV-2 infection to restarting cancer therapy was 12 and 26 days among vaccinated and non-vaccinated groups, respectively (p = 0.002). Although this study does not have enough power to perform multivariate analyses to account for confounders, it provides data on COVID-19 in non-vaccinated and vaccinated cancer patients and illustrates the potential benefits of COVID-19 vaccines for these patients.

Original languageEnglish
Article number3746
JournalCancers
Volume14
Issue number15
ISSN2072-6694
DOIs
Publication statusPublished - 08.2022

Research Areas and Centers

  • Research Area: Luebeck Integrated Oncology Network (LION)
  • Centers: University Cancer Center Schleswig-Holstein (UCCSH)

DFG Research Classification Scheme

  • 205-14 Haematology, Oncology

Coronavirus related work

  • Research on SARS-CoV-2 / COVID-19

Cite this